Country for PR: United States
Contributor: PR Newswire New York
Friday, February 26 2021 - 03:00
AsiaNet
Biocytogen announces acquisition of a third Beacon Optofluidic system to support expanding Antibody Discovery Platform
BOSTON, Feb. 26, 2021 /PRNewswire-AsiaNet/ --

Biocytogen [ 
https://c212.net/c/link/?t=0&l=en&o=3078068-1&h=1739377710&u=https%3A%2F%2Fbiocytogen.com%2F&a=Biocytogen 
], a company dedicated to accelerating therapeutic antibody discovery, has 
announced the acquisition of a third Beacon Optofluidic system. The new 
instrument, developed by Berkeley Lights, will support the expansion of 
Biocytogen's antibody discovery service platform in the greater Boston area for 
collaborations across the globe. 

Logo - https://mma.prnewswire.com/media/1358305/Biocytogen_Logo.jpg

Founded on its successful gene editing platform, Biocytogen recently developed 
humanized immunoglobulin mice that carry the full variable region repertoire 
(RenMab(TM) [ 
https://c212.net/c/link/?t=0&l=en&o=3078068-1&h=1105839884&u=https%3A%2F%2Frenmab.com%2F&a=RenMab 
] ), as well as a related common light chain strain, RenLite(TM). Generation of 
fully human antibodies in these models minimizes the time required to develop 
high-affinity antibody therapeutics with favorable pharmacokinetic properties. 
Biocytogen's integrative use of Berkeley Lights' industry-leading light-sorting 
technology further accelerates the process, due to the rapid screening of 
thousands of single B cells for antibody hit generation. Together, these 
technologies allow for the generation and discovery of fully human antibodies 
in a matter of weeks.

About Biocytogen
Biocytogen is an international biotechnology company that provides a 
comprehensive portfolio of products and preclinical services to accelerate new 
drug discovery and development. Biocytogen's expertise in gene editing has led 
to the generation of an extensive catalog of humanized mouse models that have 
been used to validate antibody drugs undergoing clinical development at its 
subsidiary, Eucure Biopharma. Biocytogen collaborates with global partners to 
discover therapeutic antibodies using its flagship RenMab(TM) model. For more 
information, please visit https://biocytogen.com/ and click the service 
brochure [ 
https://c212.net/c/link/?t=0&l=en&o=3078068-1&h=699310011&u=https%3A%2F%2Fbiocytogen.com%2Fcontent%2Fuploads%2F2021%2F02%2FBiocytogen-Antibody-Discovery-Services_2021.pdf&a=service+brochure 
].

Media Contact:
Jenna Frame 
jframe@biocytogen.com 


SOURCE  Biocytogen